Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

A Phase 1b Randomized Single-Center Trial of Topical Cerdulatinib (DMVT-502) in Patients with Mild-to-Moderate Atopic Dermatitis

ABSTRACT: A Phase 1b Randomized Single-Center Trial of Topical Cerdulatinib (DMVT-502) in Patients with Mild-to-Moderate Atopic Dermatitis

PROVIDER: PRJNA593978 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR10601224.fastq.gz	Fastqsanger.gz
	SRR10601225.fastq.gz	Fastqsanger.gz
	SRR10601226.fastq.gz	Fastqsanger.gz
	SRR10601227.fastq.gz	Fastqsanger.gz
	SRR10601228.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 16

Similar Datasets

A Phase 1b Randomized Single-Center Trial of Topical Cerdulatinib (DMVT-502) in Patients with Mild-to-Moderate Atopic Dermatitis

Project description:This phase 1b, single-center, double-blind study evaluated safety, efficacy, and effect on molecular profiles of a topical Janus kinase/spleen tyrosine kinase (JAK/Syk) inhibitor, cerdulatinib gel 0.37%, in ten adults with mild-to-moderate atopic dermatitis (AD).

2020-11-12 | GSE141570 | GEO

Synechococcus sp. CCFWC 502 isolate:CCFWC 502

Project description:Synechococcus sp. CCFWC 502 isolate:CCFWC 502 Genome sequencing and assembly

| PRJNA880272 | ENA

Safety and Efficacy of Atuzabrutinib Topical Gel in Patients with Mild-to-Moderate Atopic Dermatitis: Findings from Phase 2a Trial

Project description:This phase 2a study of atuzabrutinib (PRN473/SAR444727), a Bruton tyrosine kinase inhibitor, comprised of a double-blind placebo-controlled treatment period and an open-label uncontrolled treatment period and evaluated safety and efficacy of atuzabrutinib 5% gel vs placebo (in double-blind period) in patients with mild-to-moderate atopic. dermatitis (AD). Patients aged 18–70 years diagnosed with mild-to-moderate AD (N=39) for at least 6 months were included in the study. During the double-blinded Period (Days 1–14), two target lesions with a difference ≤1 point in total sign score (TSS) were randomized 1:1 to atuzabrutinib or matching placebo twice daily. During open-label period (Days 15–42), patients continued to treat the assigned areas and other AD-affected lesions (except scalp, palms, soles and genitals) with atuzabrutinib BID. The objective is to evaluate the safety, tolerability, PK and preliminary efficacy of atuzabrutinib in patients with mild to moderate AD. RNA sequencing analysis was performed to understand the target immune cell expression in lesional skin biopsies versus normal skin and the effect of atuzabrutinib.

2025-03-01 | GSE289784 | GEO

Safety and Efficacy of Atuzabrutinib Topical Gel in Patients with Mild-to-Moderate Atopic Dermatitis: Findings from Phase 2a Trial

Project description:Safety and Efficacy of Atuzabrutinib Topical Gel in Patients with Mild-to-Moderate Atopic Dermatitis: Findings from Phase 2a Trial

| PRJNA1224777 | ENA

Bradyrhizobium diazoefficiens strain:USDA 502 | isolate:USDA 502

Project description:Bradyrhizobium diazoefficiens USDA 502 genome sequencing

| PRJNA1344115 | ENA

Elizabethkingia anophelis 502

Project description:Elizabethkingia anophelis 502 Genome sequencing and assembly

| PRJNA176121 | ENA

Bradyrhizobium sp. UFLA03-502

Project description:Bradyrhizobium sp. UFLA03-502 Genome sequencing

| PRJNA931256 | ENA

Bradyrhizobium sp. UFLA03-502

Project description:Bradyrhizobium sp. UFLA03-502 Genome sequencing